Humacyte Inc
HUMA
Company Profile
Business description
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
Contact
2525 East North Carolina Highway 54
DurhamNC27713
USAT: +1 919 313-9633
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
220
Stocks News & Analysis
stocks
Investment decisions in overvalued bank drive strong results
Shares fall despite a broadly unchanged outlook.
stocks
Overvalued ASX share hurt by normalising conditions
Investors overly optimisitc about future prospects.
stocks
After earnings, is Amazon stock a buy, a sell, or fairly valued?
With temperature on tariffs easing and a raised fair value estimate, here’s what we think of Amazon’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,101.30 | 24.40 | 0.27% |
| CAC 40 | 7,950.18 | 124.05 | -1.54% |
| DAX 40 | 23,569.96 | 164.06 | -0.69% |
| Dow JONES (US) | 46,987.10 | 323.90 | -0.68% |
| FTSE 100 | 9,646.00 | 89.78 | -0.92% |
| HKSE | 26,391.81 | 94.09 | -0.36% |
| NASDAQ | 23,004.54 | 495.26 | -2.11% |
| Nikkei 225 | 50,822.09 | 61.59 | -0.12% |
| NZX 50 Index | 13,598.90 | 22.09 | 0.16% |
| S&P 500 | 6,728.80 | 8.48 | 0.13% |
| S&P/ASX 200 | 8,826.90 | 16.40 | 0.19% |
| SSE Composite Index | 3,996.41 | 1.15 | -0.03% |